Elsunersen - Praxis-Precision-Medicines
Alternative Names: PRAX-222Latest Information Update: 13 Aug 2025
At a glance
- Originator Praxis Precision Medicines
- Class Antiepileptic drugs; Antisense oligonucleotides
- Mechanism of Action Gene silencing; SCN2A protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Epilepsy
Most Recent Events
- 04 Aug 2025 Phase-III clinical trials in Epilepsy (In adolescents, In children, In neonates, In infants) in USA (Intrathecal) (NCT07019922)
- 28 Feb 2025 Praxis Precision Medicines plans a registrational EMBRAVE3 trial for Epilepsy in the middle of 2025 (NCT07019922)
- 13 Jan 2025 Praxis Precision Medicines announced the completion of discussions with global regulatory agencies to harmonize a registrational study design for elsunersen